BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 186 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,099,000 | +3.8% | 7,268 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $1,059,000 | +22.9% | 7,268 | 0.0% | 0.01% | +50.0% |
| Q1 2022 | $862,000 | -14.0% | 7,268 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,002,000 | -0.8% | 7,268 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,010,000 | +43.1% | 7,268 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $706,000 | +42.1% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $497,000 | -20.2% | 7,268 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $623,000 | +32.0% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $472,000 | -11.1% | 7,268 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $531,000 | +115.0% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $247,000 | -32.0% | 7,268 | +8.9% | 0.00% | 0.0% |
| Q4 2019 | $363,000 | +30.1% | 6,676 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $279,000 | -4.5% | 6,676 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $292,000 | – | 6,676 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |